MARKET

LADX

LADX

LadRx
OTCMQB
1.640
0.000
0.00%
Opening 09:30 12/04 EST
OPEN
--
PREV CLOSE
1.640
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
0.052
MARKET CAP
811.95K
P/E (TTM)
23.98
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LADX last week (1127-1201)?
Weekly Report · 2h ago
Weekly Report: what happened at LADX last week (1120-1124)?
Weekly Report · 11/27 12:32
Weekly Report: what happened at LADX last week (1113-1117)?
Weekly Report · 11/20 12:27
Watching Axos Financial; The Bear Cave Newsletter Issues Report On Co Titled "Problems At Axos Financial (AX)"
Axos financial is one of the best-performing banks of this century. The bear cave believes risks in the firm's culture, loan portfolio, and crypto ventures are not fully appreciated by the market. Axos financial has faced criticism from short-sellers in recent years.
Benzinga · 11/16 15:34
Weekly Report: what happened at LADX last week (1106-1110)?
Weekly Report · 11/13 12:18
Weekly Report: what happened at LADX last week (1030-1103)?
Weekly Report · 11/06 12:26
Weekly Report: what happened at LADX last week (1023-1027)?
Weekly Report · 10/30 12:53
Weekly Report: what happened at LADX last week (1016-1020)?
Weekly Report · 10/23 12:35
More
About LADX
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Webull offers CytRx Corporation stock information, including OTCMQB: LADX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LADX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LADX stock methods without spending real money on the virtual paper trading platform.